This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Daniel Clauw, MD; David Nashel, MD; Paul Katz, MD
Georgetown University Medical Center Washington, DC

JAMA. 1990;264(8):970-971.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

We appreciate the comments of Dr Leadbetter, Mr Birdsall, and Dr Eidson.

Dr Leadbetter's comments about the serotonin syndrome are pertinent. However, as he notes, the prominent manifestations of eosinophilia-myalgia syndrome are different from those of serotonin syndrome.

We concur with Mr Birdsall that there are a number of host factors, including possible derangements in the hypothalamic-pituitary axis, that might render an individual more susceptible to the development of eosinophilia-myalgia syndrome.¹

Dr Eidson cites recent epidemiologic evidence that suggests that the outbreak of eosinophilia-myalgia syndrome is due to a contaminant of tryptophan rather than the tryptophan itself. We agree that a contaminant may be responsible for the development of eosinophilia-myalgia syndrome and clearly stated this in our article. However, we continue to believe that abnormal tryptophan metabolism may play a role in this disease, as has been confirmed by the recent work of Silver et al.¹ . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?